Dyslipidemia and altered lipid metabolism in exocrine glands contribute significantly to the onset and progression of Sjögren's syndrome, presenting a potential target for therapeutic intervention.
Lipid metabolism disorders, including dyslipidemia and local lipid deposition in exocrine glands, are emerging as key contributors to the pathogenesis of Sjögren's syndrome.
Sjögren's syndrome (SS) is a chronic autoimmune disorder that primarily affects the exocrine glands. Due to the intricate nature of the disease progression, the exact mechanisms underlying SS are not completely understood. Recent research has highlighted the complex interplay between immune dysregulation and metabolic abnormalities in inflammatory diseases. Notably, lipid metabolism has emerged as a crucial factor in the modulation of immune function and the progression of autoimmune diseases, including SS. This review explores the prevalence of dyslipidemia in SS, emphasizing its role in the onset, progression, and prognosis of the disease. We specifically described the impact of altered lipid metabolism in exocrine glands and its association with disease-specific features, including inflammation and glandular dysfunction. Additionally, we discussed the potential clinical implications of lipid metabolism regulation, including the role of polyunsaturated fatty acids (PUFAs) and their deficits in SS pathogenesis. By identifying lipid metabolism as a promising therapeutic target, this review highlights the need for further research into lipid-based interventions for the management of SS.
Chang et al. (Tue,) conducted a review in Sjögren's syndrome. Lipid metabolism regulation was evaluated. Dyslipidemia and altered lipid metabolism in exocrine glands contribute significantly to the onset and progression of Sjögren's syndrome, presenting a potential target for therapeutic intervention.